BioSpace News Archive

Deals

Can-Fite Announces ADS Ratio Change

Can-Fite BioPharma Ltd. announced that the Company will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing two ordinary shares to a new ratio of one ADS representing thirty ordinary shares.

May 1, 2019
·
5 min read
Drug Development

Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma

COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors

May 1, 2019
·
13 min read
Business

Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update

Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million

May 1, 2019
·
21 min read
Business

Community Medical Services: Wisconsin’s First Ever 24/7-accessible Opioid Treatment Program (OTP) Opens in West Allis

The new OTP is part of a statewide strategy to utilize the 21st Century Act, which provides federal funding for innovative ways to address the opioid epidemic plaguing the nation.

May 1, 2019
·
5 min read
Business

Ana Maria Cuervo, M.D., Ph.D., Elected to the National Academy of Sciences

Dr. Cuervo is professor of developmental and molecular biology, of anatomy and structural biology, and of medicine, co-director of the Institute for Aging Research, and holds the Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases at Einstein.

May 1, 2019
·
3 min read
Business

Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus

Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors.

May 1, 2019
·
6 min read
Drug Development

Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that intravitreal administration of the Company’s novel AIM™ AAV204 capsid to non-human primates led to robust transgene expression in the inner and outer retina.

May 1, 2019
·
4 min read
Deals

Veracyte Announces Proposed Public Offering of Common Stock - May 1, 2019

Veracyte, Inc. announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

May 1, 2019
·
2 min read
Business

vTv Therapeutics Announces 2019 First Quarter Financial Results and Update

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events.

May 1, 2019
·
11 min read
AI-Based Language Service Writefull Joins Digital Science Portfolio

Digital Science, a technology company serving stakeholders across the research ecosystem, welcomes artificial intelligence (AI) based language platform, Writefull, to the Digital Science family of companies.

May 1, 2019
·
2 min read